Mirati Therapeutics Company Profile (NASDAQ:MRTX)

About Mirati Therapeutics

Mirati Therapeutics logo

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MRTX
  • CUSIP:
Key Metrics:
  • Previous Close: $6.15
  • 50 Day Moving Average: $5.56
  • 200 Day Moving Average: $5.47
  • 52-Week Range: $4.40 - $24.86
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.67
  • P/E Growth: 0.00
  • Market Cap: $114.56M
  • Outstanding Shares: 19,924,000
  • Beta: 1.15
Profitability:
  • Return on Equity: -89.06%
  • Return on Assets: -78.73%
Debt:
  • Current Ratio: 5.53%
  • Quick Ratio: 5.53%
Additional Links:
Companies Related to Mirati Therapeutics:

Analyst Ratings

Consensus Ratings for Mirati Therapeutics (NASDAQ:MRTX) (?)
Ratings Breakdown: 4 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $16.11 (180.19% upside)

Analysts' Ratings History for Mirati Therapeutics (NASDAQ:MRTX)
Show:
DateFirmActionRatingPrice TargetDetails
1/9/2017Jefferies Group LLCReiterated RatingHold$5.00View Rating Details
11/18/2016Avondale PartnersDowngradeOutperform -> Market PerformView Rating Details
11/17/2016HC WainwrightInitiated CoverageBuy$12.00View Rating Details
11/11/2016Leerink SwannReiterated RatingHold$7.00View Rating Details
11/4/2016WedbushReiterated RatingOutperform$12.00View Rating Details
8/18/2016Piper Jaffray CompaniesSet Price TargetHold$7.00View Rating Details
6/6/2016Barclays PLCLower Price TargetOverweight$41.00 -> $27.00View Rating Details
6/6/2016Citigroup Inc.Lower Price TargetBuy$30.00 -> $23.00View Rating Details
3/1/2016SunTrust Banks, Inc.Initiated CoverageBuy$32.00View Rating Details
6/1/2015Brean CapitalDowngradeBuy -> HoldView Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Mirati Therapeutics (NASDAQ:MRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
5/5/2016Q1($0.99)($1.13)ViewN/AView Earnings Details
3/9/2016Q4($1.03)($0.96)ViewN/AView Earnings Details
11/6/2015($0.88)($1.11)ViewN/AView Earnings Details
5/6/2015($0.71)($0.77)ViewN/AView Earnings Details
3/11/2015Q414($0.83)($0.77)ViewN/AView Earnings Details
11/10/2014Q314($0.76)($0.64)ViewN/AView Earnings Details
8/8/2014Q214($0.69)($0.82)ViewN/AView Earnings Details
3/18/2014Q413($0.66)($0.97)ViewN/AView Earnings Details
11/12/2013Q313($0.78)($2.95)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mirati Therapeutics (NASDAQ:MRTX)
Current Year EPS Consensus Estimate: $-4.21 EPS
Next Year EPS Consensus Estimate: $-3.44 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($1.19)($0.90)($1.01)
Q2 20165($1.21)($1.00)($1.08)
Q3 20165($1.22)($1.02)($1.10)
Q4 20165($1.22)($0.91)($1.03)
Q1 20172($1.08)($0.84)($0.96)
Q2 20172($1.10)($0.84)($0.97)
Q3 20172($1.12)($0.84)($0.98)
Q4 20172($1.16)($0.84)($1.00)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Mirati Therapeutics (NASDAQ:MRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mirati Therapeutics (NASDAQ:MRTX)
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 50.41%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/26/2017Ltd. BraslynMajor ShareholderBuy48,169$5.45$262,521.05View SEC Filing  
1/25/2017Ltd. BraslynMajor ShareholderBuy30,600$5.42$165,852.00View SEC Filing  
1/24/2017Ltd. BraslynMajor ShareholderBuy27,682$5.32$147,268.24View SEC Filing  
1/23/2017Ltd. BraslynMajor ShareholderBuy19,251$5.27$101,452.77View SEC Filing  
1/20/2017Ltd. BraslynMajor ShareholderBuy61,158$5.46$333,922.68View SEC Filing  
1/17/2017Ltd. BraslynMajor ShareholderBuy119,887$5.50$659,378.50View SEC Filing  
1/6/2017Boxer Capital, LlcMajor ShareholderBuy286,163$5.60$1,602,512.80View SEC Filing  
6/14/2016Charles M BaumCEOBuy20,000$7.05$141,000.00View SEC Filing  
6/9/2016Bros. Advisors Lp BakerMajor ShareholderSell999,358$9.41$9,403,958.78View SEC Filing  
6/7/2016Ltd. BraslynMajor ShareholderBuy376,902$9.96$3,753,943.92View SEC Filing  
5/6/2016Ltd. BraslynMajor ShareholderBuy65,782$18.21$1,197,890.22View SEC Filing  
3/28/2016Ltd. BraslynMajor ShareholderBuy20,848$19.36$403,617.28View SEC Filing  
3/18/2016Ltd. BraslynMajor ShareholderBuy1,166$19.34$22,550.44View SEC Filing  
1/15/2016Mark J. GergenCOOSell10,000$25.92$259,200.00View SEC Filing  
9/16/2015Bros. Advisors Lp BakerMajor ShareholderBuy150,000$45.00$6,750,000.00View SEC Filing  
5/26/2015Jamie ChristensenSVPSell4,750$28.07$133,332.50View SEC Filing  
3/5/2015Jamie ChristensenSVPSell6,000$25.41$152,460.00View SEC Filing  
2/19/2015Jamie ChristensenSVPSell4,750$22.84$108,490.00View SEC Filing  
2/3/2015Orbimed Advisors LlcMajor ShareholderBuy100,000$20.00$2,000,000.00View SEC Filing  
1/29/2015Bros. Advisors Lp BakerMajor ShareholderBuy425,000$20.00$8,500,000.00View SEC Filing  
7/1/2014Orbimed Advisors LlcMajor ShareholderSell107,332$21.66$2,324,811.12View SEC Filing  
11/26/2013Charles M BaumCEOBuy5,000$16.96$84,800.00View SEC Filing  
10/29/2013Orbimed Advisors LlcMajor ShareholderBuy125,000$17.50$2,187,500.00View SEC Filing  
10/24/2013Tang Capital Partners LpMajor ShareholderBuy57,143$17.50$1,000,002.50View SEC Filing  
9/20/2013Tang Capital Partners LpMajor ShareholderSell36,898$16.34$602,913.32View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Mirati Therapeutics (NASDAQ:MRTX)
DateHeadline
News IconAre Analysts Optimistic About Where Mirati Therapeutics, Inc. (NASDAQ:MRTX) is Heading? - Winfield Review (NASDAQ:MRTX)
winfieldreview.com - February 22 at 11:48 PM
News IconChart Watch for Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Midway Monitor (NASDAQ:MRTX)
midwaymonitor.com - February 22 at 11:48 PM
investornewswire.com logoStrong Sell Recommendations Of Mirati Therapeutics, Inc. (NASDAQ:MRTX) At 0 - Investor Newswire (NASDAQ:MRTX)
www.investornewswire.com - February 20 at 6:01 PM
News IconAnalysts Peer Into Their Crystal Balls For Mirati Therapeutics, Inc. (NASDAQ:MRTX): Where Is It headed? - Winfield Review (NASDAQ:MRTX)
winfieldreview.com - February 20 at 6:01 PM
News IconWatching the Technicals: Mirati Therapeutics Inc. (MRTX) - Benton Bulletin (NASDAQ:MRTX)
bentonbulletin.com - February 18 at 5:50 PM
News IconShares in Focus: Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Searcy News (NASDAQ:MRTX)
searcysentinel.com - February 17 at 4:14 PM
News IconWhat are Brokerage Firms Saying About Mirati Therapeutics, Inc. (NASDAQ:MRTX)? - Aiken Advocate (NASDAQ:MRTX)
aikenadvocate.com - February 14 at 8:18 PM
News IconInvestor Technical Review for Mirati Therapeutics Inc. (MRTX) - Baldwin Journal (NASDAQ:MRTX)
baldwinjournal.com - February 13 at 7:48 PM
finance.yahoo.com logoMirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:MRTX)
finance.yahoo.com - February 13 at 7:48 PM
biz.yahoo.com logoMIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:MRTX)
biz.yahoo.com - February 8 at 7:32 PM
News IconStock Watch: Focusing in on Mirati Therapeutics, Inc. (NASDAQ:MRTX) - The Tribune (NASDAQ:MRTX)
lakecitytribune.com - January 31 at 12:23 AM
News IconAre Insiders Bumping Up Their Positions in Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Wall Street Beacon (NASDAQ:MRTX)
wsbeacon.com - January 31 at 12:23 AM
News IconTrading Corner: Focusing in on Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Gilbert Daily (NASDAQ:MRTX)
gilbertdaily.com - January 30 at 12:10 AM
News IconShares to Watch: Indicator Update on Mirati Therapeutics Inc. (MRTX) - Rives Journal (NASDAQ:MRTX)
rivesjournal.com - January 29 at 4:46 AM
News IconWilliams %R, RSI, and ADX Update for Mirati Therapeutics Inc. (MRTX) - Sherwood Daily (NASDAQ:MRTX)
sherwooddaily.com - January 26 at 10:17 PM
News IconCCI Focus on Shares of Mirati Therapeutics Inc. (MRTX) - Sherwood Daily (NASDAQ:MRTX)
sherwooddaily.com - January 25 at 5:28 AM
News IconStock Update on Earnings & Estimates for Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Aiken Advocate (NASDAQ:MRTX)
aikenadvocate.com - January 25 at 12:27 AM
News IconAre Insiders Filling Their Own Pockets With Shares? Insider Update on Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Wall Street Beacon (NASDAQ:MRTX)
wsbeacon.com - January 23 at 11:59 PM
News IconCurious Trading Activity Sighted in Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Wall Street Beacon (NASDAQ:MRTX)
wsbeacon.com - January 14 at 1:01 AM
finance.yahoo.com logoMirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares (NASDAQ:MRTX)
finance.yahoo.com - January 11 at 7:15 PM
marketexclusive.com logoInsider Trading Activity Mirati Therapeutics, Inc. (NASDAQ:MRTX) – Major Shareholder Bought 286,163 shares of Stock (NASDAQ:MRTX)
marketexclusive.com - January 11 at 7:15 PM
investopedia.com logoMirati Launches $65M Public Stock Offering (MRTX) (NASDAQ:MRTX)
www.investopedia.com - January 9 at 7:21 PM
investopedia.com logoMirati Therapeutics Sets $65M Public Offering (NASDAQ:MRTX)
www.investopedia.com - January 9 at 7:21 PM
nasdaq.com logoMRTX Prices Offering At $5.60/Share (NASDAQ:MRTX)
www.nasdaq.com - January 9 at 4:26 AM
us.rd.yahoo.com logo7:31 am Mirati Therapeutics prices an underwritten public offering of 4,350,176 shares of its common stock at a price to the public of $5.60/share (NASDAQ:MRTX)
us.rd.yahoo.com - January 6 at 7:21 PM
publicnow.com logoMirati Therapeutics Announces Pricing Of Public Offering Of Common Stock (NASDAQ:MRTX)
www.publicnow.com - January 6 at 7:21 PM
biz.yahoo.com logoMIRATI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:MRTX)
biz.yahoo.com - January 6 at 7:21 PM
streetinsider.com logoMirati Therapeutics (MRTX) Offers Data from on Glesatinib and Sitravatinib Clinical Trials - StreetInsider.com (NASDAQ:MRTX)
www.streetinsider.com - January 6 at 1:06 AM
streetinsider.com logoMirati Therapeutics (MRTX) Plans Offering of Common Stock (NASDAQ:MRTX)
www.streetinsider.com - January 5 at 8:05 PM
finance.yahoo.com logo4:02 pm Mirati Therapeutics announces data from 2 ongoing clinical programs including the Phase 1b & Phase 2 trials of glesatinib; co intends to offer & sell shares of its common stock (NASDAQ:MRTX)
finance.yahoo.com - January 5 at 8:05 PM
biz.yahoo.com logoMIRATI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events (NASDAQ:MRTX)
biz.yahoo.com - January 5 at 8:05 PM
publicnow.com logoMirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs (NASDAQ:MRTX)
www.publicnow.com - January 5 at 8:05 PM
publicnow.com logoMirati Therapeutics Announces Proposed Public Offering of Common Stock (NASDAQ:MRTX)
www.publicnow.com - January 5 at 8:05 PM
News IconShould You Sell Carbylan Therapeutics, Inc. Based On Current Broker Views? (NASDAQ:MRTX)
baddgoddess.com - December 17 at 7:01 PM
finance.yahoo.com logoHow Mirati Therapeutics (MRTX) Stock Stands Out in a Strong Industry (NASDAQ:MRTX)
finance.yahoo.com - December 9 at 6:41 PM
News IconInvestor Focus on Technical Levels for Mirati Therapeutics Inc. (MRTX) - Yankee Analysts (NASDAQ:MRTX)
yankeeanalysts.com - December 7 at 6:36 PM
insidermonkey.com logoIs Mirati Therapeutics, Inc. (MRTX) Going to Burn These Hedge Funds? (NASDAQ:MRTX)
www.insidermonkey.com - December 7 at 9:50 AM
News IconGrowth Story Unfolding for Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Prospect Journal (NASDAQ:MRTX)
prospectjournal.com - December 6 at 9:53 AM
News IconTrend Indicator Update on Mirati Therapeutics Inc. (MRTX) - Yankee Analysts (NASDAQ:MRTX)
yankeeanalysts.com - December 6 at 9:53 AM
News IconTrading Scout: Watching Shares of Mirati Therapeutics Inc. (MRTX) - Yankee Analysts (NASDAQ:MRTX)
yankeeanalysts.com - December 2 at 6:21 PM
capitalcube.com logoMirati Therapeutics, Inc. :MRTX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 (NASDAQ:MRTX)
www.capitalcube.com - December 1 at 9:30 AM
News IconStock Momentum in Focus on Shares of Mirati Therapeutics Inc. (MRTX) - Yankee Analysts (NASDAQ:MRTX)
yankeeanalysts.com - November 23 at 6:20 PM
News IconEquity Rundown: RSI and CCI Check on Mirati Therapeutics Inc. (MRTX) - Yankee Analysts (NASDAQ:MRTX)
yankeeanalysts.com - November 23 at 9:25 AM
News IconUpdate on Valuation Formula's For Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Wall Street Lion (NASDAQ:MRTX)
wslnews.com - November 22 at 6:25 PM
News IconAnalysts Take the Wheel on Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares and Where They Might Be Headed - CSZ News (NASDAQ:MRTX)
cincysportszone.com - November 22 at 10:28 AM
News IconStock Watch: Indicators in View for Mirati Therapeutics Inc. (MRTX) - MicroCap Wired (NASDAQ:MRTX)
www.microcapwired.com - November 22 at 10:28 AM
investornewswire.com logoCan Shares Of Mirati Therapeutics, Inc. (NASDAQ:MRTX) Hit $17? - Investor Newswire (NASDAQ:MRTX)
www.investornewswire.com - November 21 at 6:46 PM
News IconTechnical Update on Shares of Mirati Therapeutics Inc. (MRTX) - Yankee Analysts (NASDAQ:MRTX)
yankeeanalysts.com - November 18 at 5:51 PM
News IconVC Score In Focus for Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Wall Street Lion (NASDAQ:MRTX)
wslnews.com - November 17 at 10:03 AM
News IconStock Watch: Indicators in View for Mirati Therapeutics Inc. (MRTX ... - Yankee Analysts (NASDAQ:MRTX)
yankeeanalysts.com - November 17 at 10:03 AM

Social

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Where is Mirati Therapeutics' stock going? Where will Mirati Therapeutics' stock price be in 2017?

9 equities research analysts have issued twelve-month target prices for Mirati Therapeutics' shares. Their predictions range from $5.00 to $32.00. On average, they expect Mirati Therapeutics' stock price to reach $16.11 in the next twelve months.

When will Mirati Therapeutics announce their earnings?

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

What are analysts saying about Mirati Therapeutics stock?

Here are some recent quotes from research analysts about Mirati Therapeutics stock:

  • Jefferies Group LLC analysts commented, "MRTX reported clinical updates on lead programs, glesatinib and sitravatinib. ID’ing glesatinib’s optimal patient pop (MET amp) as well as better safety w/ lower discontinuation rate on new formulation could start to pay off as more pts enter ph.II, which could help enable them to show whether activity is differentiated. Sitravatinib data remains early." (1/9/2017)

  • According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (1/5/2017)

Who owns Mirati Therapeutics stock?

Mirati Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Aviva Holdings Ltd. (10.00%), Broadfin Capital LLC (4.15%), Boxer Capital LLC (3.80%), Franklin Resources Inc. (1.90%), State Street Corp (0.95%) and RTW Investments LP (0.65%). Company insiders that own Mirati Therapeutics stock include Boxer Capital, Llc, Bros Advisors Lp Baker, Charles M Baum, Jamie Christensen, Ltd Braslyn and Mark J Gergen.

Who sold Mirati Therapeutics stock? Who is selling Mirati Therapeutics stock?

Mirati Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Broadfin Capital LLC and AQR Capital Management LLC.

Who bought Mirati Therapeutics stock? Who is buying Mirati Therapeutics stock?

Mirati Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Trexquant Investment LP and RTW Investments LP. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, Bros Advisors Lp Baker, Charles M Baum and Ltd Braslyn.

How do I buy Mirati Therapeutics stock?

Shares of Mirati Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Mirati Therapeutics stock cost?

One share of Mirati Therapeutics stock can currently be purchased for approximately $5.75.

Mirati Therapeutics (NASDAQ:MRTX) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Earnings History Chart

Earnings by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Dividend History Chart

Dividend Payments by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Last Updated on 2/23/2017 by MarketBeat.com Staff